{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T17:49:43Z","timestamp":1760204983004,"version":"3.41.2"},"reference-count":37,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:p>\n            The purpose of this review is to critically analyze published data evaluating the impact of azole pharmacokinetic and pharmacodynamic parameters, MICs, and\n            <jats:named-content content-type=\"genus-species\">Candida<\/jats:named-content>\n            species on clinical outcomes in patients with candidemia. Clinical breakpoints (CBPs) for fluconazole and voriconazole, which are used to determine susceptibility, have been defined by the Clinical and Laboratory Standards Institute (CLSI) for\n            <jats:named-content content-type=\"genus-species\">Candida<\/jats:named-content>\n            species.\n          <\/jats:p>","DOI":"10.1128\/jcm.01072-18","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T13:00:38Z","timestamp":1535029238000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":14,"title":["Are\n            <i>In Vitro<\/i>\n            Susceptibilities to Azole Antifungals Predictive of Clinical Outcome in the Treatment of Candidemia?"],"prefix":"10.1128","volume":"56","author":[{"given":"Twisha S.","family":"Patel","sequence":"first","affiliation":[{"name":"Michigan Medicine, Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peggy L.","family":"Carver","sequence":"additional","affiliation":[{"name":"Michigan Medicine, Ann Arbor, Michigan, USA"},{"name":"University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory A.","family":"Eschenauer","sequence":"additional","affiliation":[{"name":"Michigan Medicine, Ann Arbor, Michigan, USA"},{"name":"University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ1194"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028015590838"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1233"},{"key":"e_1_3_1_5_2","volume-title":"Clinical and Laboratory Standards Institute","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Reference method for broth microdilution antifungal susceptibility testing of yeasts. CLSI supplement M27-S4. Clinical and Laboratory Standards Institute. Wayne, PA."},{"key":"e_1_3_1_6_2","volume-title":"CLSI supplement M60","author":"Clinical and Laboratory Standards Institute","year":"2017","unstructured":"Clinical and Laboratory Standards Institute. 2017. Performance standards for antifungal susceptibility testing of yeasts, 1st ed. CLSI supplement M60. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"1"},{"key":"e_1_3_1_7_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2018. Antifungal agents breakpoint tables for interpretation of MICs. Version 9.0."},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01230-13"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02615-13"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.9.2116"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00296-07"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/24.2.235"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.19.2.435-447.2006"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.1.40"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.8.3171-3177.2005"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00474-06"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00116-08"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks482"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.07.005"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.01.014"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02566-17"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1086\/599039"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/cmi.12091"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a019752"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2010.09.002"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2018.05.001"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku124"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.10.3165-3169.2003"},{"key":"e_1_3_1_29_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2017. Voriconazole: rationale for the clinical breakpoints version 3.0. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Rationale_documents\/Voriconazole_RD_V.3_final_______Dec17.pdf."},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.44.3.819-826.2006"},{"key":"e_1_3_1_31_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2010. Voriconazole: rationale for the clinical breakpoints version 2.0. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Rationale_documents\/Voriconazole_Rationale_Document_version_2.0_March_2010.pdf."},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw099"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01083-10"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.06112-11"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.137-142.2004"},{"key":"e_1_3_1_36_2","volume-title":"Posaconazole package insert","author":"Merck & Co., Inc","year":"2015","unstructured":"Merck & Co., Inc. 2015. Posaconazole package insert. Merck & Co., Inc., Whitehouse Station, NJ."},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01354-13"},{"key":"e_1_3_1_38_2","volume-title":"Isavuconazole versus caspofungin in the treatment of candidaemia and other invasive Candida infections: the ACTIVE trial","author":"Kullberg BJ TG","year":"2016","unstructured":"Kullberg BJ TG, Pappas P, Vazquez J, Viscoli C, Ostrosky-Zeichner L, Rotstein C, Sobel J, Herbrecht R, Rahav G, Van Wijngaerden E, De Waele J, Jaruratanasirikul S, Chetchotisakd P, Kovanda L, Lademacher C, Lee M, Engelhardt M. 2016. Isavuconazole versus caspofungin in the treatment of candidaemia and other invasive Candida infections: the ACTIVE trial. Abstr European Conference of Clinical Microbiology and Infectious Diseases, Amsterdam, The Netherlands."}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.01072-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.01072-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T10:13:57Z","timestamp":1646475237000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.01072-18"}},"subtitle":[],"editor":[{"given":"Colleen Suzanne","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1128\/JCM.01072-18"],"URL":"https:\/\/doi.org\/10.1128\/jcm.01072-18","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"type":"print","value":"0095-1137"},{"type":"electronic","value":"1098-660X"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"2018-11-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01072-18"}}